Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral Sclerosis

NCT04391361 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04391361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04391361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral Sclerosis
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2020
Completion date
October 31, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, respiratory function, scopolamine